Bavencio market seen growing to $1.17 million by 2030

The global Bavencio (avelumab) market is projected to rise from $0.54 million in 2025 to $1.17 million by 2030, driven by cancer incidence, immunotherapy adoption and broader oncology use. North America led the market in 2025, while Asia-Pacific is expected to post notable growth.

Why it matters: - The Bavencio (avelumab) market is tied to rising demand for cancer therapies that harness the immune system. - Growth in this niche market signals continued expansion for PD-L1 inhibitors and immuno-oncology treatment options. - Higher cancer incidence, more oncology trials and broader biomarker-guided treatment selection are supporting market demand.

What happened: - The Business Research Company published a global Bavencio (avelumab) market report covering market size, trends and forecasts for 2026-2035. - The report estimates the market will grow from $0.54 million in 2025 to $0.63 million in 2026. - The report projects the market will reach $1.17 million by 2030. - The report places North America as the largest regional market in 2025. - The report identifies Asia-Pacific as a region with notable growth potential.

The details: - Bavencio contains avelumab, an immunotherapy agent designed to help the immune system identify and attack cancer cells by blocking PD-L1. - The historical growth rate is estimated at 16.8% CAGR from 2025 to 2026. - The forecast period growth rate is projected at 16.5% CAGR through 2030. - Drivers cited for historical growth include clinical success in immuno-oncology, regulatory approval for Merkel cell carcinoma, increased investment in cancer immunotherapy, improved patient survival rates and regulatory support for PD-L1 inhibitors. - Future growth factors include new tumor indications, broader global adoption of immunotherapy, more oncology clinical trials, better biomarker-guided treatment selection and higher oncology spending. - Expected trends include wider use of immune checkpoint inhibitors, growth in PD-L1 targeted therapies, more immunotherapy for solid tumors, combination regimens with chemotherapy and targeted drugs, and increased attention to rare cancers. - The report says the market is supported by the increasing incidence of cancer worldwide. - The American Cancer Society reported 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States in 2023. - The report covers major regions including Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report set includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated charts. - More information is available in the full market report. - A free sample of the report is available in the sample request.

Between the lines: - The market remains very small in absolute dollar terms, but the growth rate points to sustained commercial interest in a narrow oncology segment. - The emphasis on rare cancers and combination therapies suggests future demand may depend on broader clinical use beyond current approved settings. - North America's lead likely reflects stronger oncology infrastructure and faster uptake of advanced therapies.

What's next: - The market is expected to keep expanding as immunotherapy use broadens and more tumor types are studied. - Asia-Pacific could narrow the gap if cancer incidence rises and healthcare access improves. - Ongoing oncology research and biomarker-driven treatment selection will likely shape future adoption patterns.

The bottom line: - Bavencio's market outlook is growth-heavy but still niche, with expansion driven by cancer burden, immunotherapy adoption and potential new uses in oncology.